Active Recombinant Human IL18

• Cat.No.: IL18-1237H
• Product Overview: Recombinant human IL-18 produced in Yeast is a single polypeptide chain containing 157 amino acids, and having a predicted molecular mass of approximately 18.0kDa.

Specification

• Description: Interleukin 18 (IL-18) is a cytokine which identified as a costimulatory factor for production of interferon-γ (IFN-γ ) in response to toxic shock and shares functional similarities with IL-12. IL-18 is synthesized as a precursor 24-kDa molecule without a signal peptide and must be cleaved to produce an active molecule. IL-1 converting enzyme (ICE, Caspase-1) cleaves pro-IL-18 at aspartic acid in the P1 position, producing the mature, bioactive peptide that is readily released from the cells. It is reported that IL-18 is produced from Kupffer cells, activated macrophages, keratinocytes, intestinal epithelial cells, osteoblasts, adrenal cortex cells and murine diencephalon. IFN-γ is produced by activated T or NK cells and plays critical roles in the defense against microbiral pathogens. IFN-γ activates macrophages and enhances NK activity and B cell maturation, proliferation and Ig secretion. IFN-γ also induces expression of MHC class I and II antigens and inhibits osteoclast activation. IL-18 acts on T helper type-1 (Th1) T cells and in combination with IL-12 strongly induces them to produce IFN-γ . Pleiotropic effects of IL-18 have also been reported, such as, enhancement production of IFN-γ and GM-CSF in peripheral blood mononuclear cells, production of Th1 cytokines, IL-2, GM-CSF and IFN-γ in T cells, enhancement of Fas ligand expression by Th1 cells.
• Source: Yeast
• Species: Human
• Form: Lyophilized from a 0.2μm filtered solution in 50mM NaAc, 2mM DTT and 1% sucrose, pH5.5.
• Bio-activity: Induction of IFN-γ by PBMC cell in response to the recombinant human IL-18 was measured using human IFN-γ ELISA. IFN-γ producing activity of the sample cells can be varied depending on cell conditions. Optimal concentration for each application should be determined by each laboratory.
• Endotoxin: ≤1EU/μg, determined by the LAL method.
• Purity: ≥97%, as determined by SDS-PAGE and HPLC method.
• Usage: FOR RESEARCH ONLY
• Storage: Lyophilized samples are stable for greater than six months from date of receipt at -20 centigrade to -70 centigrade. The reconstituted samples can be stored under sterile conditions at 2-8 centigrade for one month or at -20 centigrade to -70 centigrade for three months without detectable loss of activity. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile PBS containing at least 0.1% human serum albumin or bovine serum albumin be added to the vial to prepare a stock solution of not less than 100μg/ml of the cytokine.

Gene Information

• Gene Name: IL18 interleukin 18 [ Homo sapiens (human) ]
• Official Symbol: IL18
• Synonyms: IGIF; IL-18; IL-1g; IL1F4; interleukin-18; IFN-gamma-inducing factor; IL-1 gamma; iboctadekin; interleukin 18 (interferon-gamma-inducing factor); interleukin-1 gamma
• Gene ID: 3606
• mRNA Refseq: NM_001243211
• Protein Refseq: NP_001230140
• MIM: 600953
• UniProt ID: Q14116
• Chromosome Location: 11q22.2-q22.3
• Pathway: African trypanosomiasis, organism-specific biosystem; Cellular roles of Anthrax toxin, organism-specific biosystem; Cytokine-cytokine receptor interaction, organism-specific biosystem
• Function: cytokine activity; protein binding

Reviews

10/15/2022

Effective in inflammation models.

08/22/2021

High stability in serum.

05/09/2019

Suitable for ELISA.

Q&As

How do researchers experimentally investigate the crosstalk between IL18 and other immune signaling pathways, such as Toll-like receptor signaling?

Co-immunoprecipitation, co-localization studies, and pathway inhibition assays decipher IL18's interactions with signaling molecules and pathways.

What assays and methodologies are employed to evaluate the potential therapeutic interventions targeting IL18 in autoimmune diseases and chronic inflammation?

Therapeutic antibody trials, in vitro drug screens, and disease model assessments assess IL18-targeted interventions in autoimmune diseases.

How are animal models and in vivo imaging techniques used to understand the kinetics of IL18-mediated immune responses and its tissue-specific effects?

Xenograft models, intravital imaging, and tissue-specific knockout approaches unravel IL18's kinetics and effects within complex in vivo environments.

Can you elaborate on the techniques used to assess the impact of IL18 on immune cell activation, migration, and effector functions?

Flow cytometry, chemotaxis assays, and functional cell assays examine IL18's impact on immune cell activation, migration, and effector functions.

Can you explain the experimental strategies used to analyze the interactions between IL18 and its receptor complex, as well as the downstream signaling events triggered by receptor engagement?

Surface plasmon resonance, mutational studies, and phosphoproteomics illuminate IL18's receptor interactions and downstream signal transduction pathways.

How are cellular and molecular techniques employed to investigate IL18's role in regulating the balance between Th1 and Th2 immune responses?

Immunophenotyping, cytokine profiling, and gene expression analyses elucidate IL18's influence on Th cell polarization and immune balance.

What experimental approaches are utilized to study the genetic and epigenetic regulation of IL18 expression in response to different stimuli?

ChIP assays, promoter analyses, and epigenetic profiling uncover the regulatory mechanisms underlying IL18 gene expression dynamics.

What methods are used to dissect the mechanisms through which IL18 contributes to the pathogenesis of inflammatory diseases and its interactions with other proinflammatory molecules?

Disease models, knockout mice, and co-stimulation studies explore IL18's involvement in inflammatory conditions and its interplay with other proinflammatory mediators.

How do researchers investigate the role of IL18 in modulating the tumor microenvironment and its potential implications for cancer immunotherapy?

Tumor models, immune profiling, and immunotherapeutic studies investigate IL18's modulation of the tumor microenvironment and its implications for cancer therapy.

Could you explain the experimental strategies used to characterize the inflammasome activation triggered by IL18 and its downstream effects on cytokine production?

Caspase assays, cytokine ELISAs, and microscopy techniques unveil the activation of inflammasomes and IL18's contribution to pyroptosis and cytokine storms.